Vertex Pharmaceuticals Incorporated – FDA EIR, Apr 29, 2015

An FDA inspection of Vertex Pharmaceuticals, Inc., located in Boston, MA, was conducted from April 21 to April 29, 2015. The inspection assessed general Current Good Manufacturing Practices (cGMP) for finished human drug products and provided pre-approval coverage for NDA #206038 (Lumacaftor/Ivacaftor fixed-dose combination tablets). The regulatory framework encompassed Compliance Program Guidance Manuals 7356.002 and 7346.832, adhering to 21 CFR Part 211.

While no significant objectionable conditions resulted in an FDA Form 483, several verbal observations and issues encountered during process characterization batches were discussed with management. Key observations included the need for proper declaration and qualification of third-party API repackaging and warehousing, and the correct disposition of inappropriately handled API stock. Modifications to the Process Validation Protocol for FDC tablets were highlighted, specifically regarding formal change management procedures for assessments, the use of production data for parametric release, and explicit minimum batch yield requirements. Further concerns involved investigating and implementing mitigation plans for dryer discharge failures (TRN 16652, 16748) and completing API analytical method transfers prior to commercialization. The FDA also recommended incorporating multivariate trending into Continuous Process Verification.

Deviations during characterization batches included equipment assembly issues leading to granulate blockage and loss of material traceability (TRN 15456), incorrect reporting of coater process parameters due to a software version mismatch (TRN 15463), and recurrent line pauses from atypical sampling and a software glitch (TRN 15467). Vertex management committed to evaluating these items and implementing appropriate corrective actions, with the understanding that failure to do so could lead to further regulatory action. The inspection concluded with a recommendation for acceptable cGMP conditions and NDA approval.